Page 78 - Read Online

Page 18 of 18 Lee et al. J Cancer Metastasis Treat 2021;7:27 https://dx.doi.org/10.20517/2394-4722.2021.58

coactivator-3. Proc Natl Acad Sci U S A 2016;113:4970-5. DOI PubMed PMC
146. Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid
cancers. J Clin Invest 2016;126:1052-66. DOI PubMed PMC
147. Lee WK, Kim WG, Fozzatti L, et al. Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer. Endocr Relat Cancer
2020;27:209-20. DOI PubMed PMC
148. Lee HJ, Lee WK, Kang CW, Ku CR, Cho YH, Lee EJ. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011)
inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer. Cancer Lett 2018;417:131-40. DOI PubMed
149. Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin
Cancer Res 2013;19:6173-82. DOI PubMed PMC
150. Zhang YX, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in
vitro and in vivo. Mol Cancer Ther 2014;13:2184-93. DOI PubMed
151. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925-36. DOI
PubMed
152. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J
Med 2016;375:1738-48. DOI PubMed
153. Valenciaga A, Saji M, Yu L, et al. Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight
2018;3:e122225. DOI PubMed PMC
154. Geng M, Yang Y, Cao X, Dang L, Zhang T, Zhang L. Targeting CDK12-mediated transcription regulation in anaplastic thyroid
carcinoma. Biochem Biophys Res Commun 2019;520:544-50. DOI PubMed
155. Zhu X, Park S, Lee WK, Cheng SY. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer. Endocr Relat
Cancer 2019;26:739-50. DOI PubMed PMC
156. Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-
driven cancer. Cell 2014;159:1126-39. DOI PubMed PMC